Genmab A/SGMABNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+68.0%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+68.0%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
13.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 793.03% |
| Q3 2025 | -83.78% |
| Q2 2025 | 624.23% |
| Q1 2025 | -89.91% |
| Q4 2024 | 44.39% |
| Q3 2024 | 570.54% |
| Q2 2024 | 3.20% |
| Q1 2024 | -86.62% |
| Q4 2023 | 8.60% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | 0.00% |
| Q4 2022 | 0.00% |
| Q3 2022 | -100.00% |
| Q2 2022 | 40.04% |
| Q1 2022 | -11.72% |
| Q4 2021 | 67.32% |
| Q3 2021 | 15.91% |
| Q2 2021 | 31.34% |
| Q1 2021 | -12.99% |
| Q4 2020 | 59.31% |
| Q3 2020 | -18.99% |
| Q2 2020 | 68.87% |
| Q1 2020 | -9.05% |
| Q4 2019 | 43.49% |
| Q3 2019 | 10.70% |
| Q2 2019 | 3.55% |
| Q1 2019 | 21.42% |
| Q4 2018 | 5.75% |
| Q3 2018 | -1.00% |
| Q2 2018 | 25.50% |
| Q1 2018 | 12.15% |
| Q4 2017 | 5.94% |
| Q3 2017 | 5.70% |
| Q2 2017 | 2.10% |
| Q1 2017 | 44.77% |
| Q4 2016 | -12.14% |
| Q3 2016 | 10.96% |
| Q2 2016 | -8.14% |
| Q1 2016 | 18.77% |